ArticleDermatology and therapy2023

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.

Timothy Fitzgerald et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.